<DOC>
	<DOCNO>NCT02141282</DOCNO>
	<brief_summary>This open-label , non-randomized , multicenter , Phase 2 study evaluate efficacy safety ABT-199 approximately 120 subject relapse refractory CLL B-cell receptor signal pathway inhibitor ( BCR PI ) treatment .</brief_summary>
	<brief_title>A Phase 2 Open-Label Study Efficacy Safety ABT-199 ( GDC-0199 ) Chronic Lymphocytic Leukemia ( CLL ) Subjects With Relapse Refractory B-Cell Receptor Signaling Pathway Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Receptors , Antigen , B-Cell</mesh_term>
	<criteria>Subject must diagnosis CLL meet 2008 Modified International Workshop Chronic Lymphocytic Leukemia National Cancer InstituteWorking Group ( iwCLL NCIWG ) criterion Subject relapsed/refractory disease indication treatment Subject refractory disease develop recurrence therapy BCR PI Subject must Eastern Cooperative Oncology Group performance score equal less 2 Subject must adequate bone marrow function Screening Subject must adequate coagulation profile , renal , hepatic function , per laboratory reference range Screening Subject undergone allogeneic stem cell transplant within past year Subject develop Richter 's transformation confirm biopsy Subject active uncontrolled autoimmune cytopenia Subject malabsorption syndrome condition preclude enteral route administration Subject human immunodeficiency virus ( HIV ) positive chronic hepatitis B hepatitis C virus require treatment Subject know contraindication allergy xanthine oxidase inhibitor rasburicase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer blood bone marrow</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>